Xenetic Biosciences (XBIO) Revenue (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Revenue came in at $806923.0 in Q1 2026, up 36.01% YoY from $593261.0 in Q1 2025, and up 5.3% on a QoQ basis from $766296.0 in Q4 2025.
Xenetic Biosciences (XBIO) Revenue (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 13 years of Revenue data on file, last reported at $806923.0 in Q1 2026.
- Quarterly Revenue rose 36.01% year-over-year to $806923.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 23.52% YoY) and the FY2025 annual result came in at $3.0 million, up 19.04% from the prior year.
- Revenue grew to $806923.0 in Q1 2026, from $766296.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $1.0 million in Q3 2025 to a low of $388993.0 in Q1 2022.
- A 5-year average of $619442.9 and a median of $611174.0 in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue soared 103.43% — and 2025, when it slipped 18.79%.
- Tracing XBIO's Revenue over 5 years: stood at $486972.0 in 2022, then jumped by 37.99% to $671963.0 in 2023, then declined by 3.44% to $648820.0 in 2024, then climbed by 18.11% to $766296.0 in 2025, then grew by 5.3% to $806923.0 in 2026.
- The last three Revenue figures came in at $806923.0 (Q1 2026), $766296.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 674.14 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | 660,601.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 660,601.00 |
| Mar 31, 2026 | 806,923.00 |
| Dec 31, 2025 | 766,296.00 |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 589,897.00 |
| Mar 31, 2025 | 593,261.00 |
| Dec 31, 2024 | 648,820.00 |
| Sep 30, 2024 | 614,243.00 |
| Jun 30, 2024 | 726,404.00 |
| Mar 31, 2024 | 510,817.00 |
| Dec 31, 2023 | 671,963.00 |
| Sep 30, 2023 | 611,174.00 |
| Jun 30, 2023 | 651,005.00 |
| Mar 31, 2023 | 605,844.00 |
| Dec 31, 2022 | 486,972.00 |
| Sep 30, 2022 | 414,250.00 |
| Jun 30, 2022 | 416,710.00 |
| Mar 31, 2022 | 388,993.00 |
| Dec 31, 2021 | 332,604.00 |
| Sep 30, 2021 | 349,269.00 |